April 30, 2025
The European Medicines Agency (EMA) has recommended marketing authorization for Tepezza (teprotumumab) for adults with moderate to severe thyroid eye disease (TED). TED is a rare […]
April 30, 2025
At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave conditional marketing authorization for Oczyesa (octreotide) for […]
April 29, 2025
TOPLINE: More than 50% of patients with primary aldosteronism had hyperparathyroidism (HPT), primarily secondary HPT. These patients also exhibited higher rates of atrial fibrillation and hypokalaemia, […]
April 29, 2025
The proportion of adolescents with overweight and obesity in England increased by 50% over 15 years, accompanied by significant increases in many related comorbidities, according to […]
April 28, 2025
Adrenalectomy significantly reduced the risk for vertebral fractures compared with conservative care in adults with mild autonomous cortisol secretion (MACS), according to data from a recent […]
April 25, 2025
TOPLINE: In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly increase the risk for falls, and combined use with glucagon-like peptide 1 […]
April 24, 2025
TOPLINE: Islet transplantation offered significant benefits in reducing mortality and other complications in patients with type 1 diabetes (T1D) over a median follow-up duration exceeding 10 […]
April 24, 2025
The “4S Pathway” offers strategies for realigning treatment goals and approaches for older adults with type 1 diabetes (T1D) or type 2 diabetes (T2D) who are […]
April 24, 2025
TOPLINE: Approximately one quarter (23.8%) of patients with difficult-to-control type 2 diabetes (T2D) had hypercortisolism, with contributing factors including older age; lower body mass index (BMI); […]